Teva Pharmaceutical Industries Ltd (NYSE:TEVA) EVP Sven Dethlefs sold 571 shares of the company’s stock in a transaction on Monday, March 19th. The stock was sold at an average price of $17.88, for a total value of $10,209.48. Following the completion of the sale, the executive vice president now owns 5,016 shares of the company’s stock, valued at $89,686.08. The transaction was disclosed in a filing with the SEC, which is available through this link.

Shares of Teva Pharmaceutical Industries stock traded down $0.18 during trading hours on Thursday, hitting $17.42. 3,806,916 shares of the company were exchanged, compared to its average volume of 16,808,838. The company has a current ratio of 0.86, a quick ratio of 0.58 and a debt-to-equity ratio of 1.91. Teva Pharmaceutical Industries Ltd has a 1 year low of $10.85 and a 1 year high of $33.82. The company has a market cap of $17,978.39, a P/E ratio of -1.07, a price-to-earnings-growth ratio of 1.54 and a beta of 0.65.

How to Become a New Pot Stock Millionaire

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings results on Thursday, February 8th. The company reported $0.91 EPS for the quarter, beating the Zacks’ consensus estimate of $0.77 by $0.14. Teva Pharmaceutical Industries had a negative net margin of 72.66% and a positive return on equity of 16.43%. The firm had revenue of $5.46 billion during the quarter, compared to the consensus estimate of $5.29 billion. During the same quarter last year, the firm earned $1.38 EPS. The firm’s revenue for the quarter was down 15.9% compared to the same quarter last year. equities research analysts predict that Teva Pharmaceutical Industries Ltd will post 2.3 earnings per share for the current fiscal year.

Several brokerages recently weighed in on TEVA. Vetr downgraded shares of Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating and set a $17.71 target price for the company. in a report on Tuesday. Jefferies Group began coverage on shares of Teva Pharmaceutical Industries in a report on Tuesday. They issued a “hold” rating and a $19.00 target price for the company. Maxim Group reaffirmed a “hold” rating on shares of Teva Pharmaceutical Industries in a report on Thursday, March 1st. ValuEngine raised shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a report on Thursday, February 15th. Finally, Wells Fargo reaffirmed a “sell” rating on shares of Teva Pharmaceutical Industries in a report on Tuesday, February 13th. Ten investment analysts have rated the stock with a sell rating, fifteen have assigned a hold rating and seven have assigned a buy rating to the company’s stock. Teva Pharmaceutical Industries has a consensus rating of “Hold” and an average target price of $20.69.

Several large investors have recently made changes to their positions in the stock. Cambridge Investment Research Advisors Inc. lifted its holdings in shares of Teva Pharmaceutical Industries by 16.9% in the 4th quarter. Cambridge Investment Research Advisors Inc. now owns 45,983 shares of the company’s stock valued at $871,000 after acquiring an additional 6,642 shares during the last quarter. Xact Kapitalforvaltning AB acquired a new stake in Teva Pharmaceutical Industries in the fourth quarter worth about $243,000. Meitav Dash Investments Ltd. acquired a new stake in Teva Pharmaceutical Industries in the fourth quarter worth about $5,017,000. MetLife Investment Advisors LLC acquired a new stake in Teva Pharmaceutical Industries in the fourth quarter worth about $1,335,000. Finally, Hoylecohen LLC acquired a new stake in Teva Pharmaceutical Industries in the fourth quarter worth about $954,000. 58.19% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: This report was first published by Watch List News and is owned by of Watch List News. If you are accessing this report on another site, it was illegally stolen and republished in violation of international copyright laws. The original version of this report can be read at https://www.watchlistnews.com/teva-pharmaceutical-industries-ltd-teva-evp-sven-dethlefs-sells-571-shares/1956777.html.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Insider Buying and Selling by Quarter for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.